World Leader in bench top flow chemistry instruments ThalesNano, Inc. introduces an “industry first” seminar series

Budapest, Hungary, London, UK, Princeton NJ, USA, September 18th, 2008. ThalesNano Inc. today announced that commencing in October, it will hold a series of unique seminars entitled, “Experience Your Chemistry in Flow”.

“Flow chemistry has already had a dramatic impact on how chemistry is performed”, said Richard Jones, Director of Product Management for ThalesNano Inc. “Still, most chemists are not sure what the benefits are or where to start. Enabling these people to run their own chemistry as part of the learning process has gotten a terrific response from companies and academic institutions thinking of making the move”.
The benefits of continuous flow technologies over conventional batch chemistry include the rapid synthesis of organic compounds, in particular under until now unrealizable hazardous reaction conditions. Further benefits include Green Chemistry by minimizing waste, energy consumption and raw material use, lab automation, and rapid scale-up from mg to kg quantities, which reduces CAPEX and OPEX while speeding time to market.

Who should attend? Executives, managers and chemists who are interested in:

• Acceleration of the synthesis of organic compounds, in particular under until now unrealizable hazardous reaction conditions
• Green Chemistry (minimizing waste, energy consumption and raw material use)
• Enhancing laboratory safety
• Lab automation, and
• Rapid scale-up from mg to kg quantities

Product Line-up: H CUBE®, H-CUBE MIDI®, X- CUBE®, X-CUBE FLASH®

Locations: Budapest, October 17th; San Diego, October 28th; San Francisco, October 31st; Philadelphia, November 4th; Boston, November 6th.

How can I sign up? registration@thalesnano.com

About ThalesNano Inc.

ThalesNano is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow reactors. The company has the widest portfolio of bench-top continuous process instruments. Its R&D 100 award winning H-Cube® continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Midi® are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation. 20 out of 20 of the largest pharmaceutical companies in the world employ ThalesNano products and technologies.
Contact: Laszlo Urge, Ph.D., CEO, e-mail: ceodirect@thalesnano.com, Telephone: +36-1-880-8500

World Leader in Bench-top Flow Chemistry Instruments ThalesNano, Inc. Closes Funding Round

Investment to be used to accelerate R&D for continuous process chemistry technologies and for further global expansion.

Budapest, Hungary, London, UK, Princeton, and San Diego, USA, September 8th, 2008. ThalesNano Inc. announced today the closing of an investment of $3.3M by a group of private and financial investors. The new private investors are Dominic Gallello, CEO of Graphisoft and Dave Tapolczay, CEO of Medical Research Council Technology and former VP of GlaxoSmithKline, the second largest pharmaceutical company worldwide. The proceeds will be used to expand R&D to further strengthen ThalesNano’s leadership position in the development and implementation of continuous process technologies from research to process development and full scale production. In addition, the company will expand commercial operations and services globally with particular emphasis on the US and Asia and increase production capacity based on the high demand for its technologies and instruments.

The benefits of continuous flow technologies over conventional batch chemistry include the rapid synthesis of organic compounds, in particular under until now unrealizable hazardous reaction conditions. Further benefits include Green Chemistry by minimizing waste, energy consumption and raw material use, lab automation, and rapid scale-up from mg to kg quantities, which reduces CAPEX and OPEX while speeding time to market.

“Dr. Laszlo Urge, CEO of ThalesNano said; “We are glad that our new investors clearly see the value creation of our business. We have shown significant growth over the last year in the core business. In addition, strategic partnerships were created with major pharmaceutical companies including Sanofi-Aventis SA to implement continuous process technologies on a wider scale. As a result of our intensified R&D, we expect our customers to realize additional benefits in terms of reducing development time, increasing cost efficiency and minimizing environmental impact”.

Dr. Ferenc Darvas, Chairman of ThalesNano Inc. said. “Our strategy of providing a disruptive technology to the industry is working and the confidence shown by our new investors further validates this. Providing integrated continuous flow solutions from discovery to full scale production will help to solve some of the key bottlenecks in the pharmaceutical, biotechnology and chemical industries.”

For more information please go to: www.thalesnano.com

About ThalesNano Inc.:

ThalesNano is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow reactors. The company has the widest portfolio of bench-top continuous process instruments. Its R&D 100 award winning H-Cube® continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Mid™ are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation. 20 out of 20 of the largest pharmaceutical companies in the world employ ThalesNano products and technologies.

Contact: Laszlo Urge, Ph.D., CEO, e-mail: ceodirect@thalesnano.com, Telephone: +36-1-880-8500

World Leader in Bench-top Flow Chemistry Instruments ThalesNano, Inc. Expands US Operations

Budapest, Hungary, London, UK, Princeton NJ, USA, September 3rd, 2008. ThalesNano Inc. today announced new locations in Philadelphia, Boston and San Diego to provide sales and support services to its rapidly expanding US customer base. With these additions, Alan Boyle is appointed Manager for Field Service for North America, and David Kwajewski will head up commercial efforts in New England and Canada Paul Whittles in the Western Region.

“Our largest market continues to grow at a very rapid pace”, said Carl Jones, Director of Sales of ThalesNano Inc. “We are delighted with the addition of these very talented and experienced individuals. Our goal is to serve our customers better and to help them to perform novel chemistries in discovery. Through close partnerships, we are also helping our users take the next step in continuous process scale up from laboratory to pilot stage and later production”.

Contact Details

Alan Boyle – Philadelphia – alan.boyle@thalesnano.com – 215-674-0606
David Kwajewski – Boston – david.kwajewski@thalesnano.com – 508-868-0034
Paul Whittles – San Diego – paul.whittles@thalesnano.com – 951-440-3198

For more information please go to: www.thalesnano.com

About ThalesNano Inc.:

ThalesNano is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow reactors. The company has the widest portfolio of bench-top continuous process instruments. Its R&D 100 award winning H-Cube® continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Mid™ are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation. 20 out of 20 of the largest pharmaceutical companies in the world employ ThalesNano products and technologies.

Contact: Laszlo Urge, Ph.D., CEO, e-mail: ceodirect@thalesnano.com, Telephone: +36-1-880-8500

World’s top 20 pharmaceutical companies deploy revolutionary H-Cube® from ThalesNano Inc.

Budapest, Hungary, London, UK, Princeton NJ, USA, July 16, 2008. ThalesNano Inc. today announced, that within three years from the original introduction of its H-Cube® product, 20 out of the top 20 pharmaceutical companies have introduced and adopted the technology.

The H-Cube® Continuous-flow Hydrogenation Reactor is a bench-top standalone hydrogenation reactor, uniquely combining continuous-flow chemistry with endogenous on-demand hydrogen generation and a disposable catalyst cartridge system. It allows safe, fast and cost-efficient hydrogenation with superior yield when compared to conventional methods. The H-Cube® and the other novel Cube series flow reactor systems developed by ThalesNano Inc. are showing tremendous benefits in the drug discovery process including shorted development time, increased cost efficiency and reduced environmental impact.

“Having all of the top 20 pharmaceutical companies as H-Cube® users is a real testimony that the instrument is changing the process of how drugs are developed and the benefits that can be derived as a result”, said Dr. Laszlo Urge, CEO of ThalesNano Inc. “Our early customers are now using our technology at multiple sites on four continents. H-Cube® has become their first line of technology for catalytic hydrogenations. After establishing our continuous process technology in the discovery labs of the life sciences industry we are moving into the early scale up and full production with the new versions of the systems.”

Dr. Ferenc Darvas, President and chairman of ThalesNano Inc. said. “It is clear that our strategy of providing a disruptive technology to the industry is working. The benefits of these technologies over conventional batch chemistry includes the rapid synthesis of organic compounds, in particular under until now unrealizable hazardous reaction conditions. Further benefits include “Green Chemistry” by minimizing waste, energy consumption and raw material use, lab automation, and rapid scale-up from mg to kg quantities, which reduces CAPEX and OPEX while speeding time to market.”

For more information please go to: www.thalesnano.com

About ThalesNano Inc.:

ThalesNano is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow reactors. The company has the widest portfolio of bench-top continuous process instruments. Its R&D 100 award winning H-Cube® continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Mid™ are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation.

Contac: Laszlo Urge, Ph.D., CEO, e-mail: ceodirect@thalesnano.com, Telephone: +36-1-880-8500

Budapest, Hungary, London, UK, Princeton NJ, USA, May 22, 2008. ThalesNano Inc. and sanofi-aventis R&D today announced the signing of a research and development collaboration agreement focusing on continuous process chemistry technologies.

The collaboration will focus on the development and implementation of continuous process technologies from research to full scale production. The purpose of the project is to study the utilization and application of ThalesNano’s integrated continuous process chemistry technologies within the sanofi-aventis drug R&D process from discovery to API production.
“We are delighted to work with sanofi-aventis R&D who have always been at the forefront of applying new methods and technologies to improve the drug discovery and development process”, said Dr. Laszlo Urge, CEO of ThalesNano Inc. “The ThalesNano continuous process technology is already well established in the discovery labs of the life sciences industry. Taking it to process scale promises tremendous benefits for our customers in terms of reducing development time, increasing cost efficiency and minimizing environmental impact”.
Dr. Christophe Daubié, head of Chemical Development for Paris area at sanofi-aventis R&D said : “this collaboration is important also because it enters into the scope of sanofi-aventis R&D strategy in terms of our constant involvement in safety considerations, quality improvement of our processes with respect to Environmental and Industrial Hygiene aspects, including Green Chemistry”.

Dr. Ferenc Darvas, President and chairman of ThalesNano Inc. said. “The benefits of continuous process chemistry over conventional batch chemistry includes the rapid synthesis of organic compounds, in particular under until now unrealizable hazardous reaction conditions. Further benefits include Green Chemistry by minimizing waste, energy consumption and raw material use, lab automation, and rapid scale-up from mg to kg quantities, which reduces CAPEX and OPEX while speeding time to market.”
For more information please go to: www.thalesnano.com

About ThalesNano Inc.:
ThalesNano is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow reactors. The company has the widest portfolio of bench-top continuous process instruments. Its R&D 100 award winning H-Cube® continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Midi™ are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation.
Contact: Laszlo Urge, Ph.D., CEO, e-mail: ceodirect@thalesnano.com, Telephone: +36-1-880-8500

About Sanofi-Aventis:
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.

Budapest Hungary, Princeton New Jersey and London, UK March 21, 2008 ThalesNano Inc. today announced the launch of the latest in its Cube™ flow reactor series, the X-Cube Flash™. This novel product is validated with several important chemistry applications. The X-Cube Flash™ will be officially unveiled in the US, at the 235th National Meeting of the of the American Chemical Society, held April 6-10 in New Orleans, LA, and in Europe at the Advances in Synthetic Chemistry conference in Frankfurt held on April 8 and 9.

The X-Cube Flash™ is designed to carry out homogenous reactions in continuous flow mode at high pressure and temperature, operating safely up to 200 bar and 350°C. This enables chemists to significantly expand the parameter space they can utilize within a regular laboratory setting. The system is also applicable for doing chemistry under supercritical conditions.

Dr. Laszlo Urge, CEO of ThalesNano commented: “We call our latest X-Cube™ reactor the “Flash”, because most reactions proceed in seconds or minutes instead of hours. The X-Cube Flash™ fulfills the need of our customers for safe high pressure and temperature homogenous reactions. In addition it can be used to scale up microwave assisted reactions quickly with little method development. Our experience shows that the system can be utilized to reduce hazardous waste production in many chemical processes. In certain chemical transformations, it also eliminates the need for using expensive and toxic heavy metal catalysts fulfilling the requirements of Green Chemistry. The pharmaceutical industry is increasingly adopting continuous processes and this system can provide a ready state of the art solution for testing and optimizing chemistries for continuous process applications on a larger scale later. The increase in productivity and chemical efficiency can result in significant cost and time savings for those R&D organizations who adopt this technology.”

“This product will be a complementary addition to our existing X-Cube™ technology. With its launch we have further diversified our continuous process technology portfolio giving ThalesNano the widest product range available in bench top flow chemistry and continuous process technology. The company is executing a complex strategy designed to provide integrated continuous flow solutions from discovery to full scale production which could help solve some of the key bottlenecks in the pharmaceutical, biotechnology and chemical industries” stated Dr. Ferenc Darvas, President and Chairman at ThalesNano.

For more information please refer to ThalesNano’s website at www.thalesnano.com